Corbus Pharmaceuticals Holdings (CRBP) Asset Utilization Ratio (2015 - 2022)
Corbus Pharmaceuticals Holdings (CRBP) posted Asset Utilization Ratio of 0.0 for Q2 2022, down 52.38% on a QoQ basis from 0.0 in Q1 2022, and down 94.66% year-over-year from 0.02 in Q2 2021.
Analysis
Corbus Pharmaceuticals Holdings (CRBP) Asset Utilization Ratio (2015 - 2022) Analysis & Trends
Corbus Pharmaceuticals Holdings has reported Asset Utilization Ratio for 8 years, with the latest figure at 0.0 in Q2 2022.
- On a quarterly basis, Asset Utilization Ratio fell 94.66% year-over-year to 0.0 in Q2 2022; TTM through Jun 2022 was 0.0, a 94.66% decrease from a year earlier, with the FY2021 full-year figure at 0.01, down 83.85% from the prior year.
- Asset Utilization Ratio was 0.0 for Q2 2022 at Corbus Pharmaceuticals Holdings, down from 0.0 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.63 in Q1 2020, with the low at 0.0 in Q2 2022.
- Average Asset Utilization Ratio over 5 years is 0.15, with a median of 0.04 recorded in 2018.
- The sharpest annual moves came in 2019 and 2021: Asset Utilization Ratio surged 958.8% in 2019, then slumped 96.3% in 2021.
- Over 5 years, Asset Utilization Ratio stood at 0.09 in 2018, then surged by 591.34% to 0.62 in 2019, then sank by 93.55% to 0.04 in 2020, then tumbled by 80.48% to 0.01 in 2021, then plunged by 85.88% to 0.0 in 2022.
- The last three Asset Utilization Ratio figures came in at 0.0 (Q2 2022), 0.0 (Q1 2022), and 0.01 (Q4 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 0.00 |
| 10 | Corbus Pharmaceuticals Holdings | 101.29 Mn | -61.98 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 0.00 |
| Mar 31, 2022 | 0.00 |
| Dec 31, 2021 | 0.01 |
| Sep 30, 2021 | 0.01 |
| Jun 30, 2021 | 0.02 |
| Mar 31, 2021 | 0.02 |
| Dec 31, 2020 | 0.04 |
| Sep 30, 2020 | 0.06 |
| Jun 30, 2020 | 0.09 |
| Mar 31, 2020 | 0.63 |
| Dec 31, 2019 | 0.62 |
| Sep 30, 2019 | 0.47 |
| Jun 30, 2019 | 0.37 |
| Mar 31, 2019 | 0.08 |
| Dec 31, 2018 | 0.09 |
| Sep 30, 2018 | 0.04 |
| Jun 30, 2018 | 0.04 |
| Mar 31, 2018 | 0.03 |
| Dec 31, 2017 | 0.05 |
| Sep 30, 2017 | 0.08 |